PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026
Teva Pharmaceuticals has announced new findings from its ongoing IMPACT-TD Registry revealing that only 23% of younger adults aged 18–29 experiencing symptoms of tardive dyskinesia (TD) alongside mood disorders received a formal diagnosis despite the condition causing substantial physical, psychological, and social burden. The real-world analysis highlights significant diagnostic gaps in one of the most debilitating movement disorders associated with certain psychiatric treatments and underscores growing concern among clinicians regarding underdiagnosis and delayed intervention in vulnerable patient populations.
The data were presented during the 2026 American Psychiatric Association Annual Meeting in San Francisco and demonstrated that approximately 85% of younger adults with mood disorders and TD symptoms experienced moderate-to-severe impact on daily life, despite low rates of formal disease recognition. Researchers believe the findings reinforce the urgent need for earlier diagnosis, improved clinical awareness, and expanded patient support strategies for individuals living with tardive dyskinesia.
IMPACT-TD Registry Highlights Serious Patient Burden
The IMPACT-TD Registry is described as the largest tardive dyskinesia study conducted to date and is designed as a three-year, prospective, non-interventional Phase IV research program examining how TD progresses over time and affects patients’ quality of life across diverse populations. The current analysis focused on adults with concomitant mood disorders, including bipolar disorder and depression, who were not receiving vesicular monoamine transporter 2 (VMAT2) inhibitor therapy at study enrollment.
Researchers found that the burden of TD extended well beyond visible involuntary movements, affecting emotional wellbeing, independence, social interaction, and overall quality of life across all adult age groups. The psychological burden appeared particularly severe among adults under the age of 60, with approximately 77% of younger adults reporting moderate-to-severe psychological impact despite lower overall movement severity scores compared with older populations.
Advertisement
The study also identified a substantial delay in disease recognition, with patients waiting an average of more than 3.5 years after abnormal involuntary movements were first observed before receiving a formal TD diagnosis. Healthcare experts warn that delayed diagnosis may contribute to prolonged patient suffering, reduced social functioning, and worsening psychiatric outcomes.
Tardive Dyskinesia Remains Widely Underdiagnosed
Tardive dyskinesia is a chronic neurological movement disorder commonly associated with prolonged use of certain psychiatric medications, particularly antipsychotic therapies used to treat schizophrenia, bipolar disorder, and major depressive disorder. The condition is characterized by repetitive, uncontrollable movements involving the face, tongue, jaw, torso, or extremities and may significantly interfere with daily functioning and emotional wellbeing.
Industry experts estimate that approximately one in four individuals receiving certain mental health therapies may develop TD symptoms, although many cases remain undiagnosed or misidentified due to overlapping psychiatric symptoms and variability in disease presentation.
Teva executives stated that the latest IMPACT-TD findings emphasize the importance of understanding the full human impact of TD beyond purely clinical symptom measurements. The company noted that identifying diagnostic gaps and improving disease awareness remain central to ongoing efforts aimed at supporting earlier intervention and improving long-term patient outcomes.
Researchers involved in the registry also highlighted the importance of understanding how TD uniquely affects patients with mood disorders across different age groups. Clinicians believe improved awareness may help healthcare providers better recognize early movement abnormalities and initiate more timely disease management strategies.
Mental Health and Neurology Research Continue Expanding
The findings arrive amid increasing focus within the pharmaceutical and neuroscience communities on improving diagnosis and treatment for movement disorders associated with psychiatric care. Tardive dyskinesia has gained greater clinical attention in recent years as newer VMAT2 inhibitor therapies and broader mental health awareness campaigns have improved recognition of the condition.
Teva continues investing in neuroscience and movement disorder research while supporting initiatives focused on understanding the real-world burden of TD across diverse patient populations. Healthcare specialists believe registry studies such as IMPACT-TD play an important role in advancing clinical understanding, identifying unmet medical needs, and improving patient-centered care strategies.
As psychiatric medicine increasingly shifts toward more comprehensive long-term patient management, experts emphasize that addressing diagnostic gaps in tardive dyskinesia may become essential for improving overall mental health outcomes and quality of life for millions of patients worldwide.
Source: Teva Pharmaceuticals press release
